drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Fourth-generation dual-target autologous chimeric antigen receptor T cells engineered to recognize CD19 on B cells and BCMA (TNFRSF17) on plasmablasts/plasma cells, inducing cytolytic depletion of autoreactive B-lineage cells to reduce autoantibody production.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous fourth-generation CAR T cells engineered to recognize CD19 and BCMA activate upon antigen binding and mediate cytolytic killing of B cells, plasmablasts, and plasma cells, thereby depleting autoreactive B-lineage populations and reducing autoantibody production.
drug_name
CD19/BCMA CAR-T cells (BH002)
nct_id_drug_ref
NCT06350110